A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom?

Chi Un Pae; David M. Marks; Changsu Han; Ashwin A. Patkar

doi:10.1016/j.pnpbp.2008.02.011

A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom?

Chi Un Pae, David M. Marks, Changsu Han, Ashwin A. Patkar

Department of Psychiatry

Research output: Contribution to journal › Letter › peer-review

4 Citations (Scopus)

Original language	English
Pages (from-to)	1087-1088
Number of pages	2
Journal	Progress in Neuro-Psychopharmacology and Biological Psychiatry
Volume	32
Issue number	4
DOIs	https://doi.org/10.1016/j.pnpbp.2008.02.011
Publication status	Published - 2008 May 15

ASJC Scopus subject areas

Pharmacology
Biological Psychiatry

Access to Document

10.1016/j.pnpbp.2008.02.011

Cite this

Pae, C. U., Marks, D. M., Han, C., & Patkar, A. A. (2008). A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom? Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32(4), 1087-1088. https://doi.org/10.1016/j.pnpbp.2008.02.011

A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression : Is there differential effect of ropinirole dose on developing psychotic symptom? / Pae, Chi Un; Marks, David M.; Han, Changsu; Patkar, Ashwin A.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, No. 4, 15.05.2008, p. 1087-1088.

Research output: Contribution to journal › Letter › peer-review

Pae, CU, Marks, DM, Han, C & Patkar, AA 2008, 'A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom?', Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 4, pp. 1087-1088. https://doi.org/10.1016/j.pnpbp.2008.02.011

Pae CU, Marks DM, Han C, Patkar AA. A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom? Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2008 May 15;32(4):1087-1088. https://doi.org/10.1016/j.pnpbp.2008.02.011

Pae, Chi Un ; Marks, David M. ; Han, Changsu ; Patkar, Ashwin A. / A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression : Is there differential effect of ropinirole dose on developing psychotic symptom?. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2008 ; Vol. 32, No. 4. pp. 1087-1088.

@article{b018e36a60324fe49fd04e4bbb17145e,

title = "A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom?",

author = "Pae, {Chi Un} and Marks, {David M.} and Changsu Han and Patkar, {Ashwin A.}",

note = "Funding Information: Dr. Pae has received research grant from GlaxoSmithKline Korea, GlaxoSmithKline, AstraZeneca Korea, Jansssen Pharmaceutcals Korea, Eli Lilly and Company Korea, Korean Research Foundation, Otsuka Korea, Wyeth Korea, and Korean Institute of Science and Technology Evaluation and Planning; has received honoraria and is on the speaker's bureaus of GlaxoSmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Jansssen Pharmaceutcals Korea, Eli Lilly and Company Korea, McNeil Consumer and Specialty Inc, and Otsuka Korea. Dr. Han has received research support from Korea Research Foundation Grant (MOEHRD) (KRF-2007-013-E00033) and from Korea University Neuropsychiatric Alumni Grant. Dr. Marks has no financial disclosures. Dr. Patkar is a consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; is on the speaker's bureau of Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; has received research support from National Institutes of Health, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, McNeil Consumer and Specialty Inc, Organon, Jazz Pharmaceuticals, and Pfizer.",

year = "2008",

month = may,

day = "15",

doi = "10.1016/j.pnpbp.2008.02.011",

language = "English",

volume = "32",

pages = "1087--1088",

journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",

issn = "0278-5846",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression

T2 - Is there differential effect of ropinirole dose on developing psychotic symptom?

AU - Pae, Chi Un

AU - Marks, David M.

AU - Han, Changsu

AU - Patkar, Ashwin A.

N1 - Funding Information: Dr. Pae has received research grant from GlaxoSmithKline Korea, GlaxoSmithKline, AstraZeneca Korea, Jansssen Pharmaceutcals Korea, Eli Lilly and Company Korea, Korean Research Foundation, Otsuka Korea, Wyeth Korea, and Korean Institute of Science and Technology Evaluation and Planning; has received honoraria and is on the speaker's bureaus of GlaxoSmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Jansssen Pharmaceutcals Korea, Eli Lilly and Company Korea, McNeil Consumer and Specialty Inc, and Otsuka Korea. Dr. Han has received research support from Korea Research Foundation Grant (MOEHRD) (KRF-2007-013-E00033) and from Korea University Neuropsychiatric Alumni Grant. Dr. Marks has no financial disclosures. Dr. Patkar is a consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; is on the speaker's bureau of Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; has received research support from National Institutes of Health, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, McNeil Consumer and Specialty Inc, Organon, Jazz Pharmaceuticals, and Pfizer.

PY - 2008/5/15

Y1 - 2008/5/15

UR - http://www.scopus.com/inward/record.url?scp=42949126634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42949126634&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2008.02.011

DO - 10.1016/j.pnpbp.2008.02.011

M3 - Letter

C2 - 18384925

AN - SCOPUS:42949126634

VL - 32

SP - 1087

EP - 1088

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 4

ER -